P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

A. Rubinstein; T. Bridges; D. McNeil; R. Tachdjian; H. Wedner; R. Wasserman; H. Leibl; C. Rabbat; R. Honigberg; L. Yel

doi:10.1016/j.anai.2017.08.195

P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

Annals of Allergy Asthma & Immunology ◽

10.1016/j.anai.2017.08.195 ◽

2017 ◽

Vol 119 (5) ◽

pp. S71

Author(s):

A. Rubinstein ◽

T. Bridges ◽

D. McNeil ◽

R. Tachdjian ◽

H. Wedner ◽

...

Keyword(s):

Primary Immunodeficiency ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Safety Study ◽

Immunodeficiency Diseases

Download Full-text

Long-term Safety of Facilitated Subcutaneous Immunoglobulin Treatment in Patients With Primary Immunodeficiency Diseases: Interim Analysis from a Post-authorization Safety Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2020.12.285 ◽

2021 ◽

Vol 147 (2) ◽

pp. AB73

Author(s):

Arye Rubinstein

Keyword(s):

Primary Immunodeficiency ◽

Interim Analysis ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Safety Study ◽

Immunodeficiency Diseases ◽

Immunoglobulin Treatment

Download Full-text

Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2018.12.354 ◽

2019 ◽

Vol 143 (2) ◽

pp. AB117

Author(s):

Arye Rubinstein ◽

Tracy A. Bridges ◽

H. James Wedner ◽

Donald McNeil ◽

Richard L. Wasserman ◽

...

Keyword(s):

Adverse Events ◽

Primary Immunodeficiency ◽

Interim Analysis ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Safety Study ◽

Immunodeficiency Diseases

Download Full-text

INTERIM RESULTS OF A POST-AUTHORIZATION SAFETY STUDY (PASS) ON THE LONG-TERM SAFETY OF FACILITATED SCIG 10% IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES IN THE US

10.26226/morressier.594a7d48d462b8028d8938ce ◽

2017 ◽

Author(s):

Kim Haines

Keyword(s):

Primary Immunodeficiency ◽

Primary Immunodeficiency Diseases ◽

Safety Study ◽

Immunodeficiency Diseases ◽

The Us

Download Full-text

ADVERSE EVENTS (AES) AND TOLERABILITY OF THE NEW HUMAN SUBCUTANEOUS IMMUNOGLOBULIN (SCIG 20%) IN PEDIATRIC PATIENTS (<18 YEARS OLD) WITH PRIMARY IMMUNODEFICIENCY DISEASES (PID)

10.26226/morressier.594a7d48d462b8028d8938c9 ◽

2017 ◽

Author(s):

Kim Haines

Keyword(s):

Adverse Events ◽

Primary Immunodeficiency ◽

Pediatric Patients ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Immunodeficiency Diseases

Download Full-text

Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases

Immunotherapy ◽

10.2217/imt-2017-0092 ◽

2017 ◽

Vol 9 (12) ◽

pp. 1035-1050 ◽

Cited By ~ 12

Author(s):

Richard L Wasserman

Keyword(s):

Primary Immunodeficiency ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Immunodeficiency Diseases ◽

Recombinant Human Hyaluronidase

Download Full-text

Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases

International Immunopharmacology ◽

10.1016/j.intimp.2019.03.034 ◽

2019 ◽

Vol 71 ◽

pp. 404-410 ◽

Cited By ~ 2

Author(s):

Todd Dumas ◽

N. Seth Berry ◽

Martin Wolfsegger ◽

Stephen Jolles ◽

Barbara McCoy ◽

...

Keyword(s):

Modeling And Simulation ◽

Primary Immunodeficiency ◽

Pharmacokinetic Modeling ◽

Population Pharmacokinetic ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Population Pharmacokinetic Modeling ◽

Immunodeficiency Diseases ◽

Dosing Intervals ◽

Pharmacokinetic Modeling And Simulation

Download Full-text

Health-Related Quality Of Life Of Japanese Patients With Primary Immunodeficiency Diseases Receiving IgPro20, a 20% Liquid Subcutaneous Immunoglobulin (Hizentra®)

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2013.12.646 ◽

2014 ◽

Vol 133 (2) ◽

pp. AB180

Author(s):

Hirokazu Kanegane ◽

Kohsuke Imai ◽

Masafumi Yamada ◽

Hidetoshi Takada ◽

Tadashi Ariga ◽

...

Keyword(s):

Quality Of Life ◽

Primary Immunodeficiency ◽

Japanese Patients ◽

Health Related Quality ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Immunodeficiency Diseases ◽

Related Quality ◽

Health Related

Download Full-text

Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials

BMC Immunology ◽

10.1186/s12865-020-00346-z ◽

2020 ◽

Vol 21 (1) ◽

Author(s):

Lisa M. Meckley ◽

Yanyu Wu ◽

Diane Ito ◽

Todd Berner ◽

Barbara McCoy ◽

...

Keyword(s):

Primary Immunodeficiency ◽

Patient Experience ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Post Hoc Analysis ◽

Immunodeficiency Diseases ◽

Post Hoc ◽

Combined Data

Download Full-text

Use of Home-Based Subcutaneous Immunoglobulin Therapy in Elderly Patients with Primary Immunodeficiency Diseases

Postgraduate Medicine ◽

10.3810/pgm.2013.01.2632 ◽

2013 ◽

Vol 125 (1) ◽

pp. 169-171 ◽

Cited By ~ 1

Author(s):

Robert M. Guthrie

Keyword(s):

Elderly Patients ◽

Primary Immunodeficiency ◽

Immunoglobulin Therapy ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Immunodeficiency Diseases ◽

Home Based

Download Full-text

Safety and efficacy of Home-Based Subcutaneous Immunoglobulin G in Elderly Patients with Primary Immunodeficiency Diseases

Postgraduate Medicine ◽

10.3810/pgm.2011.09.2474 ◽

2011 ◽

Vol 123 (5) ◽

pp. 186-193 ◽

Cited By ~ 15

Author(s):

Mark R. Stein ◽

Alan Koterba ◽

Linda Rodden ◽

Melvin Berger

Keyword(s):

Elderly Patients ◽

Primary Immunodeficiency ◽

Immunoglobulin G ◽

Subcutaneous Immunoglobulin ◽

Primary Immunodeficiency Diseases ◽

Safety And Efficacy ◽

Immunodeficiency Diseases ◽

Home Based

Download Full-text